COVID-19

As a CRO focused on clinical trials in indications with high unmet medical need, Orphan Reach has built its reputation around delivering patient centric solutions in very challenging scenarios. In light of the present urgent unmet medical need we currently face with the Covid-19 pandemic, we have been able to utilise the lessons we have learn't from rare disease trial management, to work on a COVID-19 project for a promising new therapy. We are eager to continue applying our specialised knowledge in the fight against Covid-19, one of the biggest healthcare challenges in decades.

What are we able to offer your Covid-19 project?

1. Our ability to adapt to the most challenging situations in diseases with unmet medical need has presented us with the opportunity to work on COVID-19 for a very promising new therapy

2. In partnership with our client Vicore Pharma, we have managed to obtain MHRA approval within record time, 48 hours after submission.

3. As the current pandemic is dynamic in its nature and infection rates are fluctuating globally, it becomes vital for drug developers to be ready to recruit new patients, in whichever country and whenever they become available, something Orphan Reach has extensive experience in achieving.

4. Thanks to our global presence, with reach in more than 70 countries and our nimble approach to complex challenges, combined with our existing experience in COVID-19 clinical trials, we are the ideal partner for biotech companies. Biotech companies who have no time to lose in developing their products, to deliver a much needed, effective therapy that can save many lives

5. Orphan Reach is biotech’s preferred partner when it comes to rare diseases and COVID-19, both being areas of high unmet medical need where out-of-the-box thinking and a trusted team are at the core of a successful collaboration